Nicholas C Yoder

Publication Activity (10 Years)

Years Active: 2019-2022
Publications (10 Years): 3

Top Topics

Regulatory T Cells

Photodynamic Therapy

Magnetic Resonance

Top Venues

Molecular pharmaceutics

Bioconjugate chemistry

Molecular cancer therapeutics

This page only lists publications with an associated author ORCID identifier.

Publications

Juniper A Scribner, Stuart W Hicks, Kerstin W Sinkevicius, Nicholas C Yoder, Gundo Diedrich, Jennifer G Brown, Jacquelynn Lucas, Megan E Fuller, Thomas Son, Anahita Dastur, Jeff Hooley, Christopher Espelin, Marian Themeles, Francine Z Chen, Ying Li, Michael Chiechi, Jenny Lee, Bhaswati Barat, Lusiana Widjaja, Sergey Gorlatov, James Tamura, Valentina Ciccarone, Olga Ab, Kerry A McEachem, Scott Koenig, Eric H Westin, Paul A Moore, Thomas Chittenden, Richard J Gregory, Ezio Bonvini, Deryk Loo
Preclinical Evaluation of IMGC936, a Next-Generation Maytansinoid-based Antibody-drug Conjugate Targeting ADAM9-expressing Tumors. Molecular cancer therapeutics 21 (7) (2022)
Chen Bai, Emily E Reid, Alan Wilhelm, Manami Shizuka, Erin K Maloney, Rassol Laleau, Lauren Harvey, Katie E Archer, Dilrukshi Vitharana, Sharlene Adams, Yelena Kovtun, Michael L Miller, Ravi Chari, Thomas A Keating, Nicholas C Yoder
Site-Specific Conjugation of the Indolinobenzodiazepine DGN549 to Antibodies Affords Antibody-Drug Conjugates with an Improved Therapeutic Index as Compared with Lysine Conjugation. Bioconjugate chemistry 31 (1) (2019)
Nicholas C Yoder, Chen Bai, Daniel Tavares, Wayne C Widdison, Kathleen R Whiteman, Alan Wilhelm, Sharon D Wilhelm, Molly A McShea, Erin K Maloney, Olga Ab, Lintao Wang, Shan Jin, Hans K Erickson, Thomas A Keating, John M Lambert
A Case Study Comparing Heterogeneous Lysine- and Site-Specific Cysteine-Conjugated Maytansinoid Antibody-Drug Conjugates (ADCs) Illustrates the Benefits of Lysine Conjugation. Molecular pharmaceutics 16 (9) (2019)